0001179110-18-002591.txt : 20180222 0001179110-18-002591.hdr.sgml : 20180222 20180222162538 ACCESSION NUMBER: 0001179110-18-002591 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180220 FILED AS OF DATE: 20180222 DATE AS OF CHANGE: 20180222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WALSH MATTHEW M CENTRAL INDEX KEY: 0001269428 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36867 FILM NUMBER: 18632890 MAIL ADDRESS: STREET 1: ALLERGAN STREET 2: 5 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allergan plc CENTRAL INDEX KEY: 0001578845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 BUSINESS PHONE: (216) 523-5000 MAIL ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 FORMER COMPANY: FORMER CONFORMED NAME: Actavis plc DATE OF NAME CHANGE: 20130930 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Ltd DATE OF NAME CHANGE: 20130607 4 1 edgar.xml FORM 4 - X0306 4 2018-02-20 0 0001578845 Allergan plc AGN 0001269428 WALSH MATTHEW M CLONSHAUGH BUSINESS AND TECHNOLOGY PARK DUBLIN L2 D17 E400 IRELAND 0 1 0 0 EVP, Chief Financial Officer Ordinary Shares, par value $0.0001 2018-02-20 4 A 0 13076 160.59 A 13076 D Ordinary Shares, par value $0.0001 2018-02-20 4 A 0 9340 160.59 A 22416 D Ordinary Shares, par value $0.0001 2018-02-21 4 P 0 2000 160.94 A 24416 D Performance-Based Restricted Stock Unit 2018-02-20 4 A 0 28021 0 A Ordinary Shares 28021 28021 D The reported securities are restricted share units ("RSUs"), each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 25% on each of February 20, 2019, February 20, 2020, February 20, 2021 and February 20, 2022. Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. The reported securities are RSUs, each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 20% on each of February 20, 2019, February 20, 2020, February 20, 2021, February 20, 2022 and February 20, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.80 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. /s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person 2018-02-22